Table 1.

Antiproliferative activity of the synthesized compounds (1–29) toward cancer cell lines.

Comp. no.			IC50 (μM)
	R1	R2	HeLa	FemX	K562
1	H	Ph-	4.91 3 0.99	2.20 3 0.50	5.30 3 0.08
2	2,5-di-Me	Ph-	0.74 3 0.13	0.62 3 0.13	0.34 3 0.08
3	3,4-di-Me	Ph-	2.95 3 0.27	1.84 3 0.65	0.72 3 0.19
4	3,4-di-Me	3,5-di-OMe-Ph-	2.89 3 0.24	1.17 3 0.22	0.45 3 0.01
5	3,4-di-Me	4-i-Pr-Ph-	2.84 3 0.15	1.79 3 0.01	1.12 3 0.15
6	4-i-Pr	Ph-	3.09 3 1.78	0.64 3 0.13	0.48 3 0.02
7	4-i-Pr	3,5-di-OMe-Ph-	1.98 3 0.24	0.75 3 0.21	0.45 3 0.08
8	4-i-Pr	Ch-	1.38 3 0.65	0.81 3 0.03	0.55 3 0.08
9	2,5-di-Me	Bn-	2.24 3 0.79	1.48 3 0.54	1.19 3 0.42
10	4-i-Pr	Bn-	1.37 3 0.11	0.49 3 0.21	0.34 3 0.01
11	4-i-Pr	4-OMe-Ph-	2.92 3 0.04	1.06 3 0.07	0.68 3 0.16
12	2,4-di-i-Pr	Ph-	0.68 3 0.13	0.59 3 0.15	0.38 3 0.10
13	2,4-di-i-Pr	3,5-di-OMe-Ph-	0.83 3 0.61	0.95 3 0.06	0.71 3 0.18
14	2,4-di-i-Pr	4-i-Pr-Ph	0.75 3 0.29	0.78 3 0.06	0.39 3 0.06
15	2,4-di-i-Pr	Bn-	1.52 3 0.39	1.01 3 0.09	0.73 3 0.07
16	β-tetralinyl	3,5-di-OMe-Ph-	2.67 3 0.82	1.26 3 0.29	0.70 3 0.11
17	β-tetralinyl	Ch-	2.14 3 0.30	0.99 3 0.05	0.52 3 0.13
18	β-tetralinyl	4-i-Pr-Ph-	1.80 3 0.17	1.02 3 0.09	0.41 3 0.04
19	β-tetralinyl	Bn-	1.63 3 0.44	0.80 3 0.15	0.36 3 0.01
20	β-tetralinyl	Ph-	2.11 3 0.09	0.73 3 0.16	0.52 3 0.06
21	4-n-Bu	Ph-	1.06 3 0.30	0.62 3 0.06	0.45 3 0.02
22	2,3,5,6-tetra-Me	3,5-di-OMe-Ph-	0.86 3 0.53	0.65 3 0.15	0.55 3 0.05
23	4-F	Ph-	2.99 3 0.65	0.63 3 0.32	0.55 3 0.07
24	4-Cl	Ph-	2.91 3 0.29	2.84 3 0.37	0.61 3 0.07
25	3,4-di-Cl	Ph-	2.80 3 0.07	2.30 3 0.28	0.51 3 0.10
26	4-Br	Ph-	2.29 3 0.98	2.30 3 0.33	0.40 3 0.12
27	4-OMe	Ph-	3.50 3 0.54	2.34 3 0.48	1.31 3 0.25
28	4-OMe	3,5-di-OMe-Ph-	2.55 3 0.35	0.52 3 0.09	0.38 3 0.03
29	3,5-di-Me-4-OMe	3,5-di-OMe-Ph-	1.36 3 0.38	0.76 3 0.33	0.82 3 0.35
Cisplatina	/	/	4.4 3 0.30	4.7 3 0.30	5.7 3 0.30

^aAdopted from Reference [25].